These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

747 related items for PubMed ID: 19019358

  • 1. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ.
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [Abstract] [Full Text] [Related]

  • 2. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
    Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, Diamanti-Kandarakis E.
    Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
    [Abstract] [Full Text] [Related]

  • 3. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS.
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [Abstract] [Full Text] [Related]

  • 4. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR.
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [Abstract] [Full Text] [Related]

  • 5. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS.
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [Abstract] [Full Text] [Related]

  • 6. Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS.
    Burchall GF, Piva TJ, Ranasinha S, Teede HJ.
    Thromb Haemost; 2017 Nov; 117(11):2053-2062. PubMed ID: 29202210
    [Abstract] [Full Text] [Related]

  • 7. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
    Sahu A, Tripathy P, Mohanty J, Nagy A.
    J Gynecol Obstet Hum Reprod; 2019 May; 48(5):335-339. PubMed ID: 30316907
    [Abstract] [Full Text] [Related]

  • 8. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.
    Essah PA, Arrowood JA, Cheang KI, Adawadkar SS, Stovall DW, Nestler JE.
    Fertil Steril; 2011 Aug; 96(2):501-504.e2. PubMed ID: 21733508
    [Abstract] [Full Text] [Related]

  • 9. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
    Meyer C, McGrath BP, Teede HJ.
    Diabetes Care; 2007 Mar; 30(3):471-8. PubMed ID: 17327307
    [Abstract] [Full Text] [Related]

  • 10. Adolescents with Classical Polycystic Ovary Syndrome Have Alterations in the Surrogate Markers of Cardiovascular Disease but Not in the Endothelial Function. The Possible Benefits of Metformin.
    Fruzzetti F, Ghiadoni L, Virdis A, De Negri F, Perini D, Bucci F, Giannarelli C, Gadducci A, Taddei S.
    J Pediatr Adolesc Gynecol; 2016 Oct; 29(5):489-495. PubMed ID: 27018756
    [Abstract] [Full Text] [Related]

  • 11. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.
    Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD.
    J Clin Endocrinol Metab; 2003 Feb; 88(2):576-80. PubMed ID: 12574183
    [Abstract] [Full Text] [Related]

  • 12. Metformin improves endothelial function and carotid intima media thickness in patients with PCOS.
    Kaya MG, Yildirim S, Calapkorur B, Akpek M, Unluhizarci K, Kelestimur F.
    Gynecol Endocrinol; 2015 May; 31(5):401-5. PubMed ID: 25791462
    [Abstract] [Full Text] [Related]

  • 13. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 14. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF.
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [Abstract] [Full Text] [Related]

  • 15. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
    Ye BL, Yang HY, Zhao JZ, Lin JJ, Lin WQ.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846
    [Abstract] [Full Text] [Related]

  • 16. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
    Kabil Kucur S, Gozukara I, Aksoy A, Uludag EU, Keskin H, Kamalak Z, Carlioglu A.
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
    [Abstract] [Full Text] [Related]

  • 17. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome.
    Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G.
    Fertil Steril; 2006 Feb; 85(2):420-7. PubMed ID: 16595221
    [Abstract] [Full Text] [Related]

  • 18. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
    Vieira CS, Martins WP, Fernandes JB, Soares GM, dos Reis RM, de Sá MF, Ferriani RA.
    Contraception; 2012 Sep; 86(3):268-75. PubMed ID: 22464410
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.